国产眼科器械龙头爱博医疗收购运动医学标的

Group 1 - The core point of the article is that Aibo Medical plans to acquire at least 51% of the shares of Demei Medical to expand its presence in the healthcare sector [1][2] - Aibo Medical intends to invest up to 1 billion yuan through a combination of acquisition loans and its own funds for the acquisition [2] - Demei Medical is a leading company in the sports medicine field in China, recognized as a national high-tech enterprise with 276 patented technologies [2][3] Group 2 - Aibo Medical is facing challenges in its core business areas, particularly in the OK lens and artificial lens sectors, which have seen significant price drops and negative impacts on performance [3][4] - The acquisition aims to create a dual-channel strategy combining ophthalmology and sports medicine, but there are concerns about the financial performance of Demei Medical post-acquisition [3][4] - Demei Medical's projected revenue is expected to grow from 178 million yuan in 2023 to 286 million yuan in 2025, with a turnaround from a loss of 7.08 million yuan to a profit of 23.6 million yuan [4]